.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF02_Alitretinoin.Alitretinoin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF02_Alitretinoin.Alitretinoin| name: | Alitretinoin |
| ATC code: | L01XF02 | route: | oral |
| n-compartments | 1 |
Alitretinoin (9-cis-retinoic acid) is a retinoid approved for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. It is also under investigation or historical use for AIDS-related Kaposi's sarcoma. Alitretinoin acts on both retinoid X receptors (RXRs) and retinoic acid receptors (RARs), modulating cell growth and differentiation.
Pharmacokinetic model parameters are based on healthy adults from data compiled in regulatory submissions and review articles. Published PK studies are limited; below values are derived from secondary sources and drug monographs.
Napolitano, M, et al., & Patruno, C (2022). Alitretinoin for the treatment of severe chronic eczema of the hands. Expert opinion on pharmacotherapy 23(2) 159–167. DOI:10.1080/14656566.2021.1998457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34789049
Wadler, S, et al., & Haynes, H (1999). Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. The cancer journal from Scientific American 5(3) 165–170. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10367173